The integration of LC‒MS/MS into clinical practice holds great promise for improving the diagnosis and management of liver disease by providing accurate quantification of bilirubin molecular species and other biomarkers, such as bile acids [46], oxylipins [47] and proteins such as B2M, IGFBP3, IGFALS [48] and ApoA1 [49]. This evidence concerns the gene APOA1 and liver disorder.